Hospira Inc (HSP) Earnings Preview For Tuesday's Release
Hospira Inc (NYSE:HSP) is expected to report earnings for last fiscal quarter before the opening bell on February 14, 2012.
Who They Are:
Hospira, Inc., a specialty pharmaceutical and medication delivery company, that develops, manufactures, and markets products that help improve the safety and productivity of patient care. The company was founded in 2003 and is headquartered in Lake Forest, Illinois. Hospira Inc trades an average of 1.8 million shares per day and has a marketcap of $5.7 Billion.
52 Week High: $59.20
52 Week Low: $26.92
Book Value: $19.36
Float Short: 3.82%
What To Expect:
On average, 14 analysts are expecting a drop of $-0.21 in earnings per share compared to last quarter's results of $0.66. A surprise above $0.45 per share will top the estimated per share earnings.
Wall Street is expecting results within $0.28 and $0.51 per share.
Here is a look at the fiscal year revenue for Hospira Inc. 
Recent Stock and Valuation Performance:
Looking at the price movement over the last month, the stock has moved higher in price 9.24%, and changing from last year at this time -33.78%.
The stock has done well as compared to the overall market. When comparing to the S&P 500, the year to date difference is 6.60%.
Investors have been rewarded with an increase of year-over-year revenue. Revenue reported was $3.92 billion for 2010 vs. $3.88 billion for 2009. The bottom line has falling earnings year-over-year of $357.20 million for 2010 vs. $403.90 million for 2009.The company's earnings before interest and taxes are rising with an EBIT year-over-year of $519.20 million for 2010 vs. $502.90 million for 2009.
Here is the last few quarters to get an idea how well they perform compared to estimates 
Reported earnings per share compared to the mean estimate. Differences are rounded.
Paid2Trade uses information believed to be correct, but is not guaranteed and is not independently checked for accuracy You may wish to use this article as a starting point of your own research with your financial planner.
